Venomics AI, a biotechnology startup spun out of the Indian Institute of Science, has secured $2.7 million in pre-seed funding to advance its platform that harnesses AI and experimental methods to identify therapeutic molecules derived from animal venoms.
- Raised $2.7 million in pre-seed funding
- Building Venom Atlas to map venom-derived molecules
- Plans to expand AI and lab screening for drug leads
What happened
Venomics AI, a Bengaluru-based biotech startup, has completed a $2.7 million pre-seed funding round co-led by Speciale Invest and South Park Commons, with additional support from Operators Studio. Founded in 2026 by Kartik Sunagar and Vinay Prabhu, the startup focuses on leveraging the molecular complexity of animal venoms to discover new therapeutic molecules.
The funds will be used to grow their proprietary Venom Atlas, a comprehensive molecular dataset of venom compounds, while bolstering AI algorithms and laboratory screening processes. Venomics AI also plans to expand its team across venom biology, computational research, and drug discovery to accelerate validation and optimization of potential drug candidates.
Why it matters
Animal venoms represent a largely untapped source of biologically active molecules that have evolved specificity over millions of years, making them attractive candidates for drug discovery. While some venom-derived compounds have been developed into medicines, much of this molecular diversity remains unexplored, offering significant new therapeutic potential.
India’s biotechnology sector is experiencing rapid growth, with expectations for the bioeconomy to reach $300 billion by 2030. Supportive government initiatives like the Biopharma SHAKTI scheme and increasing investor interest highlight the strengthening ecosystem for startups such as Venomics AI focused on innovative biotech solutions.
What to watch next
Venomics AI will be closely watched for the development and expansion of its Venom Atlas, which aims to create a detailed molecular map of venom compounds to drive AI-powered drug discovery. Progress in experimental validations and pilot drug candidates arising from this platform will be key indicators of the startup’s success.
Investor appetite for Indian biotech startups continues to grow, as evidenced by recent funding rounds for companies like Cellogen Therapeutics and StrainX Bioworks. Venomics AI’s trajectory will also provide insight into how integrated AI and wet-lab approaches can advance molecular drug discovery in this emerging market.